CliniWorks forms a strategic alliance with Pfizer

PfizerCliniWorks announced a strategic alliance between its Israeli subsidiary CliniWorks (Israel) Ltd. ("CliniWorks Israel") and Pfizer Inc. ("Pfizer") to jointly advance the parties' respective capabilities in working with healthcare provider organizations to identify and close clinical or quality gaps to improve population health. The two companies are partnering to develop a population health management platform solution that leverages CliniWorks' technologies in disparate data aggregation and Natural Language Processing (which interprets free text information) of de-identified healthcare data and Pfizer's scientific, clinical and disease expertise. This platform will aim to enable large medical groups and integrated delivery system institutions to deliver near real-time and more efficient and effective quality healthcare, as well improve patient engagement or activation, reaching the Centers for Medicare and Medicaid (CMS) Triple Aim. The development work will be partially supported by a grant received by CliniWorks and Pfizer from the BIRD Foundation.

Nitzan Sneh, CliniWorks CEO, said, "Pfizer's leadership position in global healthcare and patient care complements our technology capabilities and, collectively, will bring about significant efficiencies for healthcare delivery organizations involved in the continuum of patient care."

"This alliance builds on our existing relationship with CliniWorks and will allow us to collaborate with our key customers in innovative and impactful ways to potentially improve healthcare delivery and patient outcomes," said Teresa Griesing, VP North America Medical Affairs, Pfizer Global Innovation Pharma Business Unit.

About CliniWorks, Israel and CliniWorks, Inc.
CliniWorks (Israel) Ltd. is a wholly-owned subsidiary of CliniWorks, Inc. which is a global healthcare technology leader dedicated to the transformation of Big-data into actionable evidence-based decisions. CliniWorks, Inc. is privately held and based in Cambridge, Massachusetts. Its core technology has been vetted in the healthcare industry for 17 years and its leadership team has deep expertise in clinical data management. The company is dedicated to the simple, fast, and effective use of real-world evidence to accelerate clinical research, outcomes research, and improve healthcare performance, quality of care, patient-safety, compliance and adherence to meaningful use. Through the award winning Accel™ platform, CliniWorks provides actionable reports to identify gaps in clinical care across disease areas and provides a flexible user-interface to enable cohort identification for clinical trials. This technology platform has been deployed and maintained within multiple large healthcare systems nationwide and globally. Using real-world evidence, derived from millions of medical sources, CliniWorks provides healthcare organizations with tools to improve organizational performance expedite patient enrollment in clinical trials and drive research funding.

About Pfizer
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

Most Popular Now

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

Pfizer's novel COVID-19 oral antiviral treatment c…

Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on a...

Researchers reveal a strategy for next-generation …

A study led by the Garvan Institute of Medical Research has revealed a guide to developing COVID-19 vaccines that both prevent the coronavirus from infecting human cells ...

A commonly found parasite could treat certain type…

Scientists have discovered that a deadly parasite, known to cause ill health in pregnant women and immunocompromised patients, could potentially be used to treat various ...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...

Abbott launches new initiative to drive diversity …

Abbott (NYSE: ABT) today announced the launch of a new initiative designed to help create a more inclusive clinical trial ecosystem through new approaches to training, ed...

Needle-free COVID-19 vaccine shows promise

A needle-free COVID-19 vaccination could be possible, with University of Queensland scientists successfully protecting mice from the virus by administering a US-developed...

Cleveland Clinic launches first-of-its kind preven…

Cleveland Clinic researchers have opened a novel study for a vaccine aimed at eventually preventing triple-negative breast cancer, the most aggressive and lethal form of ...

Novartis to sell its Roche stake in a bilateral tr…

Novartis has agreed to sell 53.3 million (approximately 33%) Roche bearer shares in a bilateral transaction to Roche for a total consideration of USD 20.7 billion. Vas...